Life › Medicine1 min read

Researchers discover Ral GTPase pathway driving LDLR degradation in liver cells

The pathway degrades low-density lipoprotein receptors in response to dietary cholesterol, while its inhibition restored cholesterol clearance in preclinical tests.

Researchers discover Ral GTPase pathway driving LDLR degradation in liver cells
Photo: nature.com

Researchers have identified an intracellular signaling pathway regulated by Ral GTPases that controls the turnover of the low-density lipoprotein receptor (LDLR) in the liver, as reported by nature.com nature.comnature.comnature.comOpen source ↗. Chronic intake of dietary cholesterol triggers this mechanism by elevating RAS activity, which activates Ral proteins and drives the degradation of LDLR instead of allowing it to recycle back to the cell surface nature.comnature.comnature.comOpen source ↗. This regulatory circuit operates independently of transcriptional control and the PCSK9 protein nature.comnature.comnature.comOpen source ↗.

Molecular cascade and receptor routing

The activation of Ral proteins recruits the endocytic RalBP1–REPS1 complex, which directs LDLR from the cell membrane into lysosomes nature.comnature.comnature.comOpen source ↗. Within these organelles, the receptor is degraded by the lysosomal protease cathepsin A (CTSA) nature.comnature.comnature.comOpen source ↗. Simultaneously, Ral activation diverts CTSA toward lysosomes for maturation and reduces its extracellular secretion, accelerating LDLR breakdown nature.comnature.comnature.comOpen source ↗.

Experimental activation of this pathway in hepatocytes—achieved through the deletion of RalGAPB or the overexpression of constitutively active Ral mutants—lowered LDLR levels and disrupted cholesterol clearance nature.comnature.comnature.comOpen source ↗. Furthermore, analysis of human genetic data revealed that variants in this pathway correlate with altered circulating cholesterol levels nature.comnature.comnature.comOpen source ↗.

Pharmacological inhibition

To test whether the receptor destruction could be halted, researchers targeted CTSA activity in preclinical models nature.comnature.comnature.comOpen source ↗. Pharmacological inhibition of CTSA restored hepatic LDLR function and enhanced blood cholesterol clearance nature.comnature.comnature.comOpen source ↗. The authors suggest that targeting components of this pathway represents a candidate therapeutic strategy for hypercholesterolaemia and associated cardiovascular disease nature.comnature.comnature.comOpen source ↗.

Sources · 2

Found a mistake?
  1. ↩
Add RealTech as a preferred source in Google

Read also

Up next

The next story opens automatically

More
Follow us

Type at least two letters — results appear instantly

↑↓to choose↵to openescto close